PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Jean-Pierre Després Selected Research
Obesity
05/2008
Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men.
04/2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
02/2008
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
09/2007
Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery.
03/2005
Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men.
01/2004
Molecular screening of the microsomal triglyceride transfer protein: association between polymorphisms and both abdominal obesity and plasma apolipoprotein B concentration.
01/2003
Effect of the factor VII R353Q missense mutation on plasma apolipoprotein B levels: impact of visceral obesity.
01/2003
The interleukin 6-174G/C polymorphism is associated with indices of obesity in men.
01/2003
Visceral obesity attenuates the effect of the hepatic lipase -514C>T polymorphism on plasma HDL-cholesterol levels in French-Canadian men.
07/2002
Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease.
05/2002
5' flanking variants of resistin are associated with obesity.
Articles by Research Topic
Disease
11
Obesity
05/2008 - 05/2002
6
Syndrome
09/2007 - 04/2003
5
Coronary Artery Disease (Coronary Atherosclerosis)
04/2008 - 07/2002
3
Overweight
02/2008 - 11/2005
3
Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2008 - 06/2004
3
Coronary Disease (Coronary Heart Disease)
11/2007 - 03/2003
3
Myocardial Ischemia (Ischemic Heart Diseases)
03/2005 - 08/2002
2
Dyslipidemias (Dyslipidemia)
11/2005 - 04/2003
1
Atherosclerosis (Atheroma)
04/2008
1
Weight Loss (Weight Reduction)
02/2008
1
Weight Gain
02/2008
1
Aortic Valve Stenosis (Aortic Stenosis)
01/2008
1
Inflammation
01/2008
1
Atrial Fibrillation
09/2007
1
Hyperlipidemias (Hyperlipidemia)
12/2003
1
Hypertriglyceridemia
07/2002
Drug/Important Bio-Agent (IBA)
5
Glucose (Dextrose)
FDA Link
Generic
05/2008 - 07/2002
5
rimonabant
IBA
04/2008 - 11/2005
3
Apolipoproteins
IBA
04/2006 - 01/2003
3
Lipoproteins (Lipoprotein)
IBA
03/2005 - 01/2004
2
Interleukin-6 (Interleukin 6)
IBA
05/2008 - 01/2003
2
HDL Cholesterol
IBA
01/2004 - 01/2003
2
C-Reactive Protein
IBA
04/2003 - 03/2003
1
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
IBA
05/2008
1
Insulin (Novolin)
FDA Link
05/2008
1
Carbon Monoxide
IBA
02/2008
1
Adiponectin
IBA
01/2008
1
oxidized low density lipoprotein
IBA
01/2008
1
Triad resin
IBA
01/2008
1
Cholesterol
IBA
11/2007
1
LDL Cholesterol
IBA
04/2006
1
LDL Receptors (LDL Receptor)
IBA
01/2006
1
11-beta-Hydroxysteroid Dehydrogenase Type 1
IBA
10/2004
1
Cholesterol Ester Transfer Proteins
IBA
06/2004
1
microsomal triglyceride transfer protein
IBA
01/2004
1
Sex Hormone-Binding Globulin
IBA
06/2003
1
Gemfibrozil (Lopid)
FDA Link
Generic
04/2003
1
LDL Lipoproteins (beta Lipoproteins)
IBA
03/2003
1
Lipase (Acid Lipase)
IBA
01/2003
1
Factor VII (Proconvertin)
IBA
01/2003
1
Lipoprotein(a)
IBA
08/2002
1
Resistin
IBA
05/2002
Therapy/Procedure
2
Transplants (Transplant)
09/2007 - 07/2005
2
Coronary Artery Bypass (Coronary Artery Bypass Surgery)
09/2007 - 08/2007